ROSEN, LEADING TRIAL ATTORNEYS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

Group 1 - The Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of REGENXBIO, Inc. securities between February 9, 2022, and January 27, 2026 [1] - Investors who purchased REGENXBIO securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A lead plaintiff must move the Court by April 14, 2026, to represent other class members in the litigation [3] Group 2 - The lawsuit alleges that REGENXBIO provided misleading information regarding its gene therapy product candidate RGX-111, which is intended for treating severe Mucopolysaccharidosis Type I [5] - Defendants made positive assertions about RGX-111's trial success based on favorable biomarker and safety data while concealing material adverse facts about the trial's efficacy and safety [5] - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading statements [5] Group 3 - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4] - The firm has been recognized for its success in securities class action settlements, being ranked No. 1 by ISS Securities Class Action Services in 2017 and consistently in the top 4 since 2013 [4]